Globus Medical (NYSE: GMED) is a company that develops and sells products for patients with musculoskeletal disorders. As a leader in its field, the company is preparing to announce its second-quarter financial results. The earnings release is scheduled for after the market closes on Thursday, August 6, 2026, with a conference call for investors to follow.
Ahead of the earnings report, analysts have updated their views on Globus Medical. RBC Capital maintains an "Outperform" rating but lowered its price target to $115.00 from $120.00, as highlighted by TheFly. Separately, Truist Financial set a new price target of $100.00, which represented a 23.69% potential upside from the stock's price of $80.85 at the time.
From a valuation standpoint, Globus Medical has a trailing price-to-earnings (P/E) ratio of 17.70. This metric suggests investors are paying $17.70 for every $1 of the company's annual earnings. This corresponds to an earnings yield of 5.63%, which represents the percentage of each dollar invested that was earned by the company.
The company's price-to-sales ratio is 3.35, comparing its stock price to its revenues. In terms of financial stability, Globus Medical has a very low debt-to-equity ratio of 0.02. This indicates that the company uses very little debt to finance its assets, relying more on equity from shareholders.
Globus Medical's liquidity appears strong, with a current ratio of 4.56. The current ratio measures a company's ability to pay its short-term obligations due within one year. A ratio of 4.56 means the company has $4.56 in current assets for every $1 of its current liabilities, showing a solid financial cushion.
